The study looked at – and has significantly enhanced – current diagnostic procedures for mapping brain glucose metabolism. The results were generated by measuring blood glucose levels and metabolic products in healthy subjects several times during a period of around 90 minutes. In contrast to existing procedures, the subjects did not receive radiolabelled glucose but a quantity of a harmless glucose solution equivalent to a can of a fizzy drink. As this substance does not produce a direct signal for the MR imaging method used, concentrations and metabolism of glucose were measured indirectly based on the drop in signal intensity for the product concerned. "The main advantage of this indirect method is that it can be used on other MR devices without any difficulties, because no additional hardware components are required, as is the case with other, comparable approaches," explained principal investigator Wolfgang Bogner of the Department of Biomedical Imaging and Image-guided Therapy at MedUni Vienna, highlighting the clinical significance of the research findings.
Carried out by researchers from the Department of Psychiatry and Psychotherapy and Department of Medicine III at MedUni Vienna, the study used the university’s high-performance 7-Tesla MRI scanner. The device entered operation in 2008 and is still the only ultra-high-field MR scanner available in Austria. Wolfgang Bogner and his team have already demonstrated that the novel approach also works on 3-Tesla MR scanners. "That was an important step, because 3T MR systems are extremely widespread in clinical applications," said Fabian Niess, lead author of the follow-up study.
Abnormalities in glucose metabolism are a feature of many common diseases. It is already known that cancer and tumour cells consume far greater amounts of glucose than normal cells – an effect that physicians can capitalise on when diagnosing and localising tumours. At present, this is done by means of positron emission tomography in combination with computed tomography (PET-CT), where patients have to be injected with a small amount of radioactive glucose. However, the findings will have to be verified in further studies before the new, less-invasive method developed at MedUni Vienna can be deployed for the benefit of patients.
MEDICA-tradefair.com; Source: Medical University of Vienna
